Donald Cross, MD
Cardiovascular Disease · Waco, TXNPI 1447256110
Payments from drug & device makers
Across 251 payments — averaging $1474.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Currax Pharmaceuticals LLC$168K
- AstraZeneca$163K
- Alnylam Pharmaceuticals Inc.$11K
- Philips North America LLC$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boston Scientific$2K
- plus $11K from 27 others
What the payments were for
- Consulting fees$1,2005%
- Speaking & faculty fees$6,00026%
- Travel & lodging$4,19718%
- Food & beverage$11,36250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Currax Pharmaceuticals LLC | 36 | $167,872 |
| AstraZeneca | 12 | $162,878 |
| Alnylam Pharmaceuticals Inc. | 2 | $10,600 |
| Philips North America LLC | 18 | $8,891 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Boston Scientific | 37 | $2,412 |
| Medtronic(2 entities) | 39 | $1,802 |
| Penumbra, Inc. | 5 | $1,455 |
| Terumo Medical Corporation | 10 | $1,311 |
| Abiomed | 13 | $1,212 |
| Abbott | 17 | $979 |
| Biotronik Inc. | 6 | $681 |
| Cardiovascular Systems Inc. | 9 | $651 |
| Shockwave Medical, Inc | 4 | $630 |
| Boehringer Ingelheim International GmbH | 5 | $551 |
| Inari Medical, Inc. | 2 | $258 |
| Novartis | 9 | $217 |
| Johnson & Johnson | 2 | $213 |
| Bayer | 2 | $212 |
| Impulse Dynamics (USA) Inc. | 1 | $131 |
| Pfizer | 2 | $97 |
| Actelion Pharmaceuticals US, Inc. | 5 | $76 |
| Flowphysix Inc | 1 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| Novo Nordisk | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectranetics Undiv$6,000
- Indigo$1,306
- IGT_D Systems$1,279
- Impella$841
- (9520) IGT Devices Undivided$800
- AVVIGO Guidance System$669
- GLIDESHEATH SLENDER$659
- GlideWire$507
- Peripheral Orbital Atherectomy System$456
- CoreValve Evolut$401
- IGT D Peripheral$400
- GENERAL VASCULAR ACCESS$393
- ONYX FRONTIER$373
- Vascular Lithotripsy$354
- CARDIOMEMS$327
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$325
- OPTIMIZER$262
- Orsiro$258
- Pulsar$258
- PRO-Kinetic Energy$258
How this compares
$370,164 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 593 | $479,294 |
| XareltoRivaroxaban | 165 | $172,777 |
| EntrestoSacubitril/Valsartan | 152 | $128,024 |
| Repatha SureclickEvolocumab | 116 | $95,046 |
| FarxigaDapagliflozin Propanediol | 51 | $39,474 |
| JardianceEmpagliflozin | 51 | $38,880 |
| MultaqDronedarone Hcl | 18 | $17,944 |
| Praluent PenAlirocumab | 26 | $14,607 |
| Metoprolol Succinate | 745 | $11,681 |
| Ranolazine ErRanolazine | 112 | $8,007 |
| BrilintaTicagrelor | 13 | $7,967 |
| Atorvastatin Calcium | 521 | $6,279 |
| Rosuvastatin Calcium | 359 | $5,506 |
| ClopidogrelClopidogrel Bisulfate | 368 | $5,326 |
| Carvedilol | 657 | $4,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $479,294593 claims |
| Johnson & JohnsonXarelto | $213 | $172,777165 claims |
| NovartisEntresto | $217 | $128,024152 claims |
| AstraZenecaFarxiga, Brilinta | $162,878 | $47,44164 claims |
| Boehringer IngelheimJardiance | $23 | $38,88051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Waco
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.